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Epidemiological data suggest a sexual dimorphism in Parkinson disease (PD), with
women showing lower risk of developing PD. Vulnerability of the nigrostriatal pathway
may be influenced by exposure to estrogenic stimulation throughout fertile life. To
further address this issue, we analyzed the progression of nigrostriatal damage,
microglia and astrocyte activation and microglia polarization triggered by intrastriatal
injection of dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) in male, female and
ovariectomized (OVX) mice, as well as in OVX mice supplemented with 17βestradiol
(OVX+E). Animals were sacrificed at different time points following 6-OHDA injection
and brain sections containing striatum and substantia nigra pars compacta (SNc)
underwent immunohistochemistry for tyrosine hydroxylase (TH) (dopaminergic marker),
immunofluorescence for IBA1 and GFAP (markers of microglia and astrocyte activation,
respectively) and triple immunoflorescent to identify polarization of microglia toward the
cytotoxic M1 (DAPI/IBA1/TNFα) or cytoprotective M2 (DAPI/IBA1/CD206) phenotype.
SNc damage induced by 6-OHDA was significantly higher in OVX mice, as compared
to all other experimental groups, at 7 and 14 days after surgery. Astrocyte activation
was higher in OVX mice with respect the other experimental groups, at all time points.
Microglial activation in the SNc was detected at earlier time points in male, female
and OVX+E, while in OVX mice was detected at all time-points. Microglia polarization
toward the M2, but not the M1, phenotype was detected in female and OVX+E
mice, while the M1 phenotype was observed only in male and OVX mice. Our results
support the protective effects of estrogens against nigrostriatal degeneration, suggesting
that such effects may be mediated by an interaction with microglia, which tend to
polarize preferentially toward an M2, cytoprotective phenotype in the presence of intense
estrogenic stimulation.
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INTRODUCTION
Parkinson disease (PD) is one of the most common
neurodegenerative disease of aging, neuropathologically
characterized by progressive loss of dopaminergic neuron in the
substantia nigra pars compacta (SNc) and depletion of dopamine
in the striatum (Blandini et al., 2007). The pathogenetic
mechanisms of PD are broadly described, with inflammation,
apoptosis, aging and oxidative stress playing crucial roles
(Blandini, 2013).
Epidemiological and biological data suggest the existence of a
sexual dimorphism for PD: women show lower risk of developing
PD, and their age at disease onset tends to be higher (Nitkowska
et al., 2014). These differences are likely mediated by sex
steroid hormones, estrogens in particular. Earlier observations
have described an inverse correlation between estrogen levels
and severity of PD symptoms (Currie et al., 2004), and the
incidence and prevalence of PD is higher in postmenopausal
than in premenopausal women of the same age (Currie et al.,
2004; Ragonese et al., 2006a). Moreover, a significant correlation
between age at PD onset and menopause has been reported, as
well as an increased risk of PD in conditions causing reduced
cumulative exposure to endogenous estrogens (early menopause,
reduced fertile life length) (Ragonese et al., 2006a,b). Estrogen
replacement therapy is associated with reduction of symptoms
severity or lesser risk of developing PD (Tsang et al., 2001);
by contrast the risk for PD increases in women with surgical
menopause (Benedetti et al., 2001) or undergoing ovariectomy
prior to menopause (Rocca et al., 2008). Thus, exposure to
estrogen activity during lifetime may modify brain sensitivity to
degeneration, influencing disease onset.
Estrogen neuroprotective effects have been widely reported
in a number of neuronal cell systems, including the nigrostriatal
dopaminergic neurons, via both genomic and non-genomic
mechanisms (Morale et al., 2006). Several studies in
animal models showed a positive influence of estrogens on
neurodegeneration related to their anti-inflammatory and
anti-apoptotic effects (Gillies and McArthur, 2010; Habib and
Beyer, 2014; Villa et al., 2016). Effects on glial reactivity might
be particularly relevant, as glial cell activation (microglial,
in particular) may substantially contribute to progression
of neuronal damage in PD (Armentero et al., 2006; Hirsch
and Hunot, 2009; Whitton, 2010; Carta and Pisanu, 2013;
Sanchez-Guajardo et al., 2013).
Activated microglia can be polarized and, depending on the
modulatory effects of the microenvironment, driven toward
different phenotypes: a cytotoxic, M1 or a neuroprotective,
M2 phenotype (Hu et al., 2012; Blandini, 2013; Franco and
Fernández-Suárez, 2015), two extremes of a range of intermediate
phenotypes that microglia acquire in response to a myriad of
physiological stimuli. Although mouse models are extensively
used for macrophage/microglia research, translation to the
human can be problematic, since human macrophage system
remains poorly described. However, it is clear that the subsets
between human being and mouse are similar but not identical
(Ingersoll et al., 2010; Italiani and Boraschi, 2014; Zhang et al.,
2017). Prolonged activation, as it seems to occur in PD, may
promote the release of complement proteins, chemokines and
cytokines, which activate M1 inflammatory responses with
neurotoxic effects (Su and Federoff, 2014), thereby sustaining
the neuronal degeneration in PD (Lull and Block, 2010).
Their proliferation and activation, characterized by peculiar
morphological changes and release of soluble factors (Colburn
et al., 1997), is central to the maintenance of the immune
homeostasis of the brain. Ovariectomy induces a decrease levels
of estrogen receptor-α (ER-α) and an increase in the expression
of neuroinflammatory markers, which are reduced by estrogen
replacement therapy (Labandeira-Garcia et al., 2016).
Classic murine PD models, based on intracerebral infusion
of 6-hydroxydopamine (6-OHDA) in rats or systemic
administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) to mice, have been used to explore the role of
glial activation associated with nigrostriatal damage and the
modulatory effects estrogens. In rats receiving an intrastriatal
injection of 6-OHDA, which induces prompt damage of striatal
terminals followed by delayed loss of SNc neurons (Domanskyi
et al., 2011; Blandini and Armentero, 2012), microglia activation
precedes cell loss in the SNc (Armentero et al., 2006) and shows
a typical temporal profile, characterized by initial expression of
the M2 phenotype progressively replaced by the M1 phenotype,
as the nigral cell loss begins to manifest (Ambrosi et al., 2017).
In MPTP-intoxicated mice, estrogen treatment have proven
able to counteract the PD-like neuropathological alterations
induced by the toxin by acting on dopaminergic neurons, either
directly or through modulation of astroglial and microglial
activation (Tripanichkul et al., 2006; Yadav et al., 2014). Through
a slight modification of the classic 6-OHDA model (rat),
Virgone-Carlotta et al. (2013) explored microglial activation in
wildtype or transgenic C57BL/6N mice that received intrastriatal
6-OHDA. They demonstrated a direct crosstalk between SNc
neurons and microglia that may trigger a microphagocytic
activity toward dopaminergic neurons; also in this case, full
microglia activation preceded maximum dopaminergic cell loss
(Virgone-Carlotta et al., 2013).
In this study, we sought to investigate the potential
estrogen modulation on glial reactivity during the progression
of nigrostriatal degeneration in C57BL/6N mice exposed to
unilateral intrastriatal injection of 6-OHDA. To examine the
estrogen effects on the degree of glia activation and microglia
polarization during the neurodegenerative process, we usedmale,
female and ovariectomized (OVX) female mice treated with 17β-
estradiol or placebo. The choice of using mice instead of rats,
for the 6-OHDA model, was due to the necessity of testing the
experimental design in animals (mice) suitable for subsequent
studies in transgenic models.
MATERIALS AND METHODS
Animals
All experiments procedures were carried out in accordance with
the European Communities Council Directives (2010/63/EEC;
D.L., 27.01.1992, number 116) and the guidelines for animal
experimentation approved by the Animal Care Committees of
the University of Pavia. Maximum care was taken to limit
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the number of animals used in this study. Male and female
C57BL/6N mice, 7–10 weeks old, were used (Charles River,
Italy). Female mice were in proestrous stage, as determined
by cytological assessment of vaginal lavage (McLean et al.,
2012), when undergoing the experimental procedures. (OVX)
C57BL/6N female mice (7 weeks) were also obtained directly
from Charles River.
Animals were housed two per cage at the Centralized
Animal Facility of the University of Pavia, under controlled
conditions of light (12-h light/dark cycle) and temperature
(20–22◦C), with free access to food and water. Upon arrival,
mice were left in the housing facilities for at least 1 week
before the beginning of any experimental procedures. All
animals received an estrogen-free diet (AIN93M Mucedola).
One week after the ovariectomy, OVX mice were implanted
with subcutaneous pellets (Innovative Research of America) that
constantly released physiologic amounts of 17β-estradiol (17β-
estradiol, 0.010mg/day/mouse) (OVX+E) or placebo (Vegeto
et al., 2006). The estrogen treatment in OVX+E mice was
maintained throughout the experimental paradigm, until mice
were sacrificed.
Surgery
Mice were anesthetized with Equithesin (3ml/kg i.p.) and
placed in a stereotaxic frame (Stoelting, Wood Dale, IL,USA)
completed with a mouse adaptor. Eight micrograms of 6-OHDA
in 4 microliters of sterile saline solution containing 0.02% of
ascorbic acid (Sigma, USA) were injected into the right striatum
(+0.4mm anterior, +1.8 lateral and −3.5mm ventral with
respect to bregma and dura) at 0.5µL/min, using a Hamilton
10-µL syringe with a 26-gauge needle (Domanskyi et al., 2011;
Virgone-Carlotta et al., 2013). After injection, the needle was
left in place for 5 min before being retracted to allow complete
diffusion of the medium, and wounds were clipped. In OVX
and OVX+E groups, 6-OHDA was injected 2 weeks after the
ovariectomy and 1 week after pellet implantation.
Male, female, OVX, and OVX+E mice were sacrificed 1, 2,
7, and 14 days after injection of the neurotoxin (n = 7 for
each group, at each time point). Time points were selected
in accordance to previously published data that demonstrate
the most suitable time point to detect the onset of the
neurodegenerative and neuroinflammatory processes (Virgone-
Carlotta et al., 2013; Muñoz-Manchado et al., 2016).
Themajor advantage of using a neurotoxic PDmodel based on
unilateral injection of 6-OHDA is the possibility to compare the
lesioned side with the intact side, used as a negative control for
histological analyses (Schober, 2004). Additionally, a substantial
dopaminergic lesion can be prompted with 6-OHDA, whereas
bilateral MPTP-induced lesions are less marked and sometimes
more difficult to quantify. We thus exploited this experimental
model of PD to clarify the role of estrogen on nigrostriatal
vulnerability and to eventually extend these observations to
transgenic models in future studies.
Tissue Processing
At sacrifice, animals were deeply anesthetized (Equithesin
3ml/kg i.p.) and received a transcardiac perfusion of saline
followed by 80 ml of ice-cold 4% paraformaldehyde (Merck
VWR, Stockholm, Sweden). Brains were removed, post-fixed
for 24 h in the same fixative and subsequently transferred in
solutions of sucrose at increasing concentrations (up to 30%) over
a 72 h period. Brains were frozen on dry ice, and stored at−80◦C.
Coronal brain sections containing the SNc and striatum were
cut at 30µm on a freezing sliding microtome (SM 200R, Leica,
Milan; Italy) and stored at −20◦C in a solution containing 30%
ethylene glycol, 20% glycerol and 0.05mol/L sodium phosphate
buffer until use.
The nigrostriatal lesion was assessed by
immunohistochemistry for the dopaminergic marker tyrosine
hydroxylase (TH) on coronal sections of both SNc and striatum.
Sections were processed with rabbit anti-TH primary antibody
(AB152, Millipore, 1:500) and a biotinylated anti-rabbit
IgG secondary antibody (Vector Laboratories, 1:500) and
revealed using a commercial kit based on the avidin-biotin
technique (Vectastain ABC Elite kit, Vector Laboratories).
Reaction products were developed using nickel-intensified
3′-3′-diaminobenzedine tetra-hydrochloride (DAB Substrate Kit
for Peroxidase, Vector Laboratories).
Assessment of neuroinflammation in the SNc was performed
by glial and dopaminergic cells triple immunofluorescent labeling
on sections containing SNc as follows: (1) sections were mounted
on slides, dried at room temperature (RT) for 30min and
washed with phosphate buffered saline (PBS); (2) sections were
blocked 1 h at RT in PBS containing 10% normal horse serum
(NHS) and 0.3% Triton X-100 (TX-100) at RT; (3) sections
were incubated overnight at 4◦C in PBS/1% NHS/0.3% TX-100
containing a mixture of a mouse anti-TH antibody (MAB318,
diluted 1:500, Chemicon) and either a goat anti-IBA1 antibody
(microglial marker, diluted 1:300, Santa Cruz Biotechnology) or
a rabbit anti-glial fibrillary acidic protein (GFAP; marker for
astrocytes, diluted 1:300, Dako); (4) sections were rinsed in PBS
and incubated 1 h at RT in PBS/1% NHS containing a mixture
of Alexa Fluor 594 conjugated donkey anti-mouse IgG antibody
(1:300) and Alexa Fluor 488 conjugated donkey anti goat IgG
antibody (1:300) or Alexa Fluor 488 conjugated donkey anti
rabbit IgG antibody (1:300) and Alexa Fluor 594 conjugated
donkey anti mouse IgG. (1:300) (Molecular Probes, Carlsbad,
CA, USA); (5) sections were rinsed in PBS and covered with
Prolong containing DAPI to label cell nuclei.
Microglia polarization was assessed by triple
immunofluorescent labeling on sections containing SNc as
follows: (1) sections were mounted on slides, dried 30 min at
RT and washed with PBS; (2) sections were blocked 1 h at RT in
PBS containing 10% NHS and 0.3% TX-100 at RT; (3) sections
were incubated overnight at 4◦C in PBS/1% NHS/0.3% TX-100
containing a mixture of a goat anti-IBA1 antibody (marker for
microglia, diluted 1:300, Santa Cruz Biotechnology) and either a
rabbit anti TNFα or a rabbit anti CD206 antibody (both diluted
1:300, Novus and Santa Cruz Biotechnology, respectively); (4)
sections were rinsed in PBS and incubated 1 h at RT in PBS/1%
NHS containing a mixture of Alexa Fluor 488 donkey anti goat
IgG antibody (1:300) and Alexa Fluor 594 donkey anti rabbit IgG
antibody (1:300) e (5) sections were rinsed in PBS and covered
with Prolong containing DAPI to label cell nuclei.
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Negative immunofluorescent controls were performed




Image analysis was performed using an AxioSkop2 microscope
connected to a computerized image analysis system (AxioCam
MR5) equipped with a dedicated software (AxioVision Rel
4.2). The number of TH+ neurons in the SNc was counted
bilaterally on every fifth section throughout the entire nucleus
using the unbiased stereological optical fractionator method
(Stereo Investigator System, Microbrightfield Inc.). Results were
expressed as the percentage of TH+ cells in the lesioned SNc with
respect to the intact side.
The 6-OHDA-induced loss of striatal dopaminergic terminals
was evaluated by considering the striatal volume deprived of TH
staining, as described previously (Blandini et al., 2007). Briefly,
both the entire striatal area and the lesioned area were measured
in every fourth section, throughout the whole rostro-caudal
extension of the striatum.
Astroglia and Microglia Activation
The evaluation of the activation of astroglia and microglia within
the SNc was determined by a qualitative analysis, observing SNc
sections stained for GFAP or IBA1 at the microscope under
medium magnification (20X). This analysis provides 4 activation
stages, characterized by different morphological features and
cell density (“0” = none; “+” = mild; “++” = moderate;
“+++” = severe), according to criteria previously described
(Ambrosi et al., 2017).
Moreover, cell count for microglia was performed by
analyzing three different SNc sections, chosen according to their
rostro-caudal coordinates. Cell density was assessed by counting
IBA1+ cells from picture (0.04mm2 frame, 40x magnification)
taken from the same areas of the same SNc section. This analysis
was performed only in OVX and OVX+E groups because in
these experimental groups we observe significant differences in
the progression of nigrostriatal degeneration and glia activation
as compared to the other experimental groups.
Statistical Analysis
All values are expressed as mean ± SEM. Statistical evaluation
of data was performed using a dedicated software (Prism 3
software, GraphPad Software). The differences between groups
were analyzed by Two-way analysis of variance (ANOVA)
followed by Bonferroni post-hoc test. Statistical significance was
set at p < 0.05.
RESULTS
Estrogen Effect on 6-OHDA-Induced
Nigrostriatal Degeneration
The intrastriatal infusion of 6-OHDA caused progressive loss
of TH+ terminals and cell bodies in the ipsilateral nigrostriatal
pathway, increasing significantly at 7 and 14 days after surgery,
as compared to the early time points in all experimental
groups (Figure 1). No cell loss was observed in the contralateral
hemisphere. In the injected (right) striatum, loss of dopaminergic
terminals stabilized at day 14 post-injection (Figure 1A). Male
and OVX mice showed slightly higher levels of striatal damage
compared to female and OVX+E mice, at all time points,
although the difference did not reach statistical significance.
The loss of dopaminergic neurons in the SNc was expressed
as a reduction in the number of TH+ neurons in the SNc of
the injected (right) hemisphere as compared to the SNc of the
intact hemisphere. Progressive, time-dependent loss of TH+
neurons was detected in the SNc of all experimental groups.
Cell loss in the SNc was significantly higher at 7 and 14 days
after the 6-OHDA infusion, as compared to earlier time points
(Figure 1B). No significant differences were observed between
male and female mice in the extent of dopaminergic cell loss in
FIGURE 1 | (A) Time course of striatal lesion. Histograms represent the
percentage (%) of the striatal volume deprived of TH staining, compared to the
entire striatum in the lesioned hemisphere. In the striatum, loss of TH+
terminals was present 24 h after 6-OHDA injection (25%) in the lesioned side,
as compared to the contralateral hemisphere, and significantly increase at day
7 and 14 post-surgery with respect the early time points. Data are expressed
as mean ± SEM. Two way ANOVA (F = 2.816) post-hoc Bonferroni test:
$p < 0.05 vs. 24 h; +p < 0.05 vs. 2 days; *p < 0.05 vs. 24 h. (B) Time course
of TH-positive neurons loss in SNc. Histograms represent the loss (%) of
TH-positive neurons of SNc in the lesioned hemisphere, compared with the
SNc of the intact hemisphere. In the lesioned SNc, depletion of TH+ cell
bodies was below 20% until day 2 and significantly increase at day 7 and 14
post-surgery with respect to the early time points. Data are expressed as
mean ± SEM. Two way ANOVA (F = 1.195) post-hoc Bonferroni test:
$$$p < 0.001 vs. 24 h; +++p < 0.001 vs. 2 days; p < 0.05 vs. 2 days;
£p < 0.05 vs. OVX+E and female; &p < 0.05 vs. male.
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the SNc. Dopaminergic cell loss was significantly increased in
the right SNc of OVX mice 24 h, 7 and 14 days after surgery
(Figure 1B), as compared to the other experimental groups.
Interestingly, treatment with 17β-estradiol (OVX+E mice)
reduced the dopaminercic cell loss, as compared to OVX mice,
with values remaining in the range of those observed in male and
female mice. In keeping with the findings of Virgone-Carlotta
et al. (2013), showing a 25 and 30% loss of dopaminergic neuron
at 4 and 7 days post-6-OHDA, respectively, we observed a
dopaminergic cell loss, in male and in female mice, of 30% at day
7 and 40% at day 14 post-6-OHDA.
Estrogen Effects on Neuroinflammation in
the SNc
Astrocytes
Astroglial and microglial activation in the SNc was assessed by
qualitative morphological analysis and cell density evaluation
(Tables 1, 2). No signs of astrocyte activation could be detected in
the intact contralateral hemisphere of lesioned animals, with cells
observed mainly around the SNc and no increase in cell density
(Figure 2A).
In both male and female lesioned animals, a time-dependent
increase in astrocyte activation, paralleling the progression of
dopaminergic cell loss, was observed in the SNc of the injected
hemisphere (Figures 2B,C). The intercellular space decreased
TABLE 1 | Time course of astrocyte activation in the substantia nigra pars
compacta following 6-OHDA infusion.
Experimental
groups
1 day 2 days 7 days 14 days
Males 0/+ + +/++ ++
Females 0/+ + ++ ++
OVX + ++ ++/+++ ++/+++
OVX+E + + ++ ++
The stages of astroglial activation were assessed according to the Colburn’s scale. [0,
resting stage; 0/+, astroglial cells are branched, but does not increase the cell density; +,
astroglial cells are branched and decreases the intercellular space; + /++, intermediate
state between stage 1 activation (+) and 2 (++);++, astroglial cells lose the ramifications
and increases the cell density].
TABLE 2 | Time course of microglia activation in the substantia nigra pars
compacta following 6-OHDA infusion.
Experimental
groups
1 day 2 days 7 days 14 days
Males + + 0 0
Females + + 0 0
OVX +/++ + + ++
OVX+E +/++ + 0/+ 0/+
The stages of microglia activation were assessed according to the Colburn’s scale. [0,
resting stage; 0/+, microglial cells are branched, but does not increase the cell density;+,
microglial cells are branched and decreases the intercellular space; + /++, intermediate
state between stage 1 activation (+) and 2 (++);++, microglial cells lose the ramifications
and increases the cell density].
both around and in the SNc, and astroglia displayed a clearly
activated state, with increased GFAP expression, rounder cell
bodies with thickening and reductions of projections, which
evolved with time after 6-OHDA injection (Figures 2B,C;
Table 1). Significant activation was observed 7 and 14 days after
surgery as compared to earlier time points (Table 1).
Astrocyte activation was higher in OVX mice with respect
the other experimental groups, at all time points. Notably, 17β-
estradiol (OVX+E) clearly reduced the astrogliosis compared to
that observed in OVX mice.
Microglia
No microglia activation was observed in the left SNc of lesioned
animals. A time-dependent activation was observed in the SNc
of the injected (right) hemisphere, which differed from that
observed for astroglia (Table 2). In male and female lesioned
mice, microglia activation increased immediately after 6-OHDA
injection, with cells showing a slight increase in IBA1 expression
and a reduction in the intracellular space. Activation peaked 2
days after the neurotoxic insult and then decreased, returning
to a baseline, resting phenotype 7 and 14 days after surgery
(Table 2).
A higher activation state was observed at day 1 post-injection
in OVX and OVX+E mice, compared to male and female mice,
with microglia showing rounder bodies, less ramification and
increased cell density both in and around the SNc of the injected
hemisphere (Table 2, Figure 3B). This microgliosis extended
throughout all time points considered in OVX mice.
Treatment with 17β-estradiol had no effect on the initial
activation of microglia cells, but strongly shortened its duration,
with microglia displaying an almost resting morphology 7 and
14 days after 6-OHDA injection in OVX+E mice. The pattern
of microglia activation observed in OVX and OVX+E was
associated with the increase of cell count. OVX lesioned mice
show a significantly increased of IBA1+ cells density as compared
to OVX+E, at 24 h and 2 days after surgery. Moreover, it was
observed a significant increase of IBA1+cells in OVX group at
24 h and 2 days after surgery as compared to the later time points
(Figure 3A).
Microglia Polarization
Polarization of activated microglia was assessed using TNF-
α and CD206 markers of microglia M1 (cytotoxic) and
M2 (cytoprotective) phenotypes, respectively (Figure 4). These
markers were not observed in resting microglia. No signs of
activation were detected in the contralateral, intact hemisphere.
Table 3 shows the evaluation of microglia polarization in the
different time points after the neurotoxic injection, and Figure 4
shows a representative images of microglia polarization.
Our data indicate that activated microglia cells displaying
a cytoprotective phenotype (CD206+) were detected in the
ipsilateral SNc 1 day after neurotoxin infusion (Table 3), in all
experimental groups, independently of gender (male or female)
or treatment (OVX or OVX+E). A sex-related difference could,
however, be clearly observed 2 days after 6-OHDA injection.
A switch from the M2 cytoprotective to the M1 cytotoxic
phenotype, evidenced by the expression of TNF-α in activated
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FIGURE 2 | Activation of astrocytes was evaluated in the lesioned (right) SNc. This figure show a representative immunofluorescent images of the right SNc at
different state of astroglia activation, determined by a qualitative analysis. Green signal: GFAP+ cells (astroglia); red signal: TH+ cells (dopaminergic neurons); blue
signal: DAPI (nuclei). Astroglia activation stage 0 (A), astroglia activation stage ++ (B) and astroglia activation stage +++ (C) (scale bar 20 µm).
FIGURE 3 | (A) Time-course of IBA1+ cell density in the lesioned (right) SNc. Approximately 800 cells/mm2 were detected in in the right SNc of OVX animals at all
time points except for day 7 post-surgery. Results are expressed as mean ± SEM. Two way ANOVA (F = 4.22): *p < 0.05 vs. OVX+E; **p < 0.01 vs. OVX+E;
$p < 0.05 vs. OVX 7 days after surgery. (B) Representative immunofluorescent images of the right SNc at different state of microglia activation. Green signal: IBA1+
cells (microglia); red signal: TH+ cells (dopaminergic neurons); blue signal: DAPI (nuclei). Microglia activation stage 0 (A); microglia activation stage + (B); microglia
activation stage ++ (C). Scale bar: 20µm.
microglia, was detected mainly in males, while a cytoprotective,
CD206+ phenotype, was maintained in females.
A switch toward the M1 phenotype could also be detected
in OVX mice at day 2, which was maintained throughout the
experimental paradigm in activated microglia cells. Notably,
treatment with 17β-estradiol (OVX+E mice) prevented
the switch toward the M1 phenotype. Activated microglia
maintained mainly CD206 expression, indicative of an M2,
protective phenotype, at all time points in the ipsilateral the SNc
of OVX+E mice (Table 3).
DISCUSSION
Many neurodegenerative diseases - including PD - show
a sexual dimorphism, the risk of developing the disease
being higher in men (Wooten et al., 2004). While it is
now accepted that neuroinflammation plays a crucial role in
the pathobiology of PD, the role of gender on onset and
progression of PD and the effects of estrogens treatment on
the neuroinflammatory response associated with PD are still
unclear. Additionally, consistent evidence from experimental
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FIGURE 4 | Representative immunofluorescent images of microglia polarization in the SNc. Images show a different phenotype of activated microglia polarization both
evaluated in lesioned SNc: M1, cytotoxic (A) and M2, cytoprotective (B); (C,D) are representative images of the intact side of SNc. Green signal: IBA1+ cells
(microglia); red signal: TNFα (M1) or CD206 (M2); blue signal: DAPI (nuclei) (scale bar 20µm).
TABLE 3 | Time course of microglia polarization in the substantia nigra pars
compacta following 6-OHDA infusion.
Experimental
groups
1 day 2 days 7 days 14 days
Males CD206 (M2) TNFα (Ml) 0 0
Females CD206 (M2) CD206 (M2) 0 0
OVX CD206 (M2) TNFα (Ml) TNFα (Ml) TNFα (Ml)
OVX+E CD206 (M2) CD206 (M2) CD206 (M2) CD206 (M2)
All cells expressing the TNFα or CD206 antigen were also positive for microglial marker
IBA1.
studies confirm the neuroprotective effects of estrogen in
neurodegeneration. Incidence and prevalence of PD are slightly
lower in premenopausal women, compared to men, but
then increase after menopause (Currie et al., 2004; Ragonese
et al., 2006a,b). Moreover, a reduced lifetime exposure of the
nigrostriatal pathway to estrogens is associated with increased
severity of PD symptoms, which can be further exacerbated after
menopause (Cereda et al., 2013). It is described that women with
a long fertile life tend to show a later onset of PD (Ragonese et al.,
2004). Nevertheless, the association between the lack of estrogen
observed after menopause and the progression of PD causes in
women an higher risk of developing other complication, such as
dyskinesia compared to men (Picillo et al., 2017). Clinical studies
have been focused on the correlation between lifetime exposure
to estrogens and risk of developing PD, as estrogen levels
may influence the synthesis and release of dopamine, thereby
modulating expression and function of dopamine receptors
(Smith and Dahodwala, 2014). Clinical trial have demonstrated
that estrogen replacement therapy is usually safe and well-
tolerated at least for the short time treatment, while longer ones
are necessary to define the effects of estrogens in PD and their
eventually side effects. Moreover, other trials demonstrated mild
efficacy of estrogens therapy in improving motor disability and
motor fluctuations in PD post-menopausal women (Blanchet
et al., 1999; Strijks et al., 1999; Tsang et al., 2000; Nicoletti
et al., 2007; Parkinson Study Group POETRY Investigators,
2011). However, in a complex neurodegenerative disease, such
as PD, it is difficult to translate the results from preclinical
models to clinical studies, probably due to the presence of
persistent stimuli, derived from endogenous different factors
that contribute to increase neuroinflammation and consequently
neuorodegeneration. Currently, the research in this field is still
relevant because other studies are necessary to clarify the effective
role of estrogens in PD, with the final goal to improve a tailored
treatment for PD patients.
Experimental studies suggest a positive influence of estrogens
on neurodegenerative diseases, possibly due to their anti-
inflammatory, anti-apoptotic and cytoprotective effects (Habib
and Beyer, 2014; Villa et al., 2016), in strict correlation with
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estrogen doses and formulations as well as timing and length of
the dosing period (Shulman, 2002).
In this work, we have explored howmanipulations of estrogen
levels in females influence the vulnerability of the nigrostriatal
pathway, focusing on the neuroinflammatory response associated
with nigrostriatal degeneration. To pursue this goal, we have
compared the nigrostriatal degeneration induced by intrastriatal
infusion of 6-OHDA and changes in astrocyte and microglia
activation/polarization in adult male and female mice, and OVX
mice treated with estrogens or placebo.
Previous studies showed that smaller reductions of striatal
dopamine are caused by neurotoxins when these are injected at
the stage of the estrous cycle with maximal levels of estradiol
(proestrus), compared to the diestrus (Yu and Liao, 2000; Datla
et al., 2003; Dluzen andHorstink, 2003; Gillies et al., 2014). In our
study, 6-OHDA infusion caused significant loss of dopaminergic
terminals and neurons at 7 and 14 days after surgery, as compared
to the earlier time points. We did not observed significant
differences, in the striatal damage induced by 6-OHDA, between
male and female mice, although the loss of dopaminergic
terminals seemed to bemore pronounced inmale andOVXmice.
By contrast, in previous studies, it was observed, that 2 weeks
after administration of 1µg 6-OHDA into the medial forebrain
bundle, the depletion of both dopamine levels in the striatum
and loss of dopaminergic neurons in the SNc was significantly
greater in male rats compared to females (Murray et al., 2003;
McArthur et al., 2007; Gillies et al., 2014). In particular, the
progressive damage of dopaminergic cells over 5 weeks after
lesion was also greater in 6-OHDA-treated male rats compared
to females, demonstrating a sex difference. Probably, these sex
differences are evident only after partial lesions (<60%) with
moderate concentrations of 6-OHDA (Gillies and McArthur,
2010; Gillies et al., 2014). It is also possible that the different strain
and neurotoxin regimen used in our study may account for this
discrepancy.
Experimental models of neuroinflammation suggest that
estrogens target primarily microglia (Vegeto et al., 2001, 2006;
Johann and Beyer, 2013) and astroglia cells (Cerciat et al.,
2010; De Marinis et al., 2013) in neurodegenerative diseases.
Estrogen protect the nigrostriatal pathway in MPTP-intoxicated
mice and the hormone response can be mediated by estrogen
receptors express on microglia and astroglia cells, because
estrogen receptors were not localized on TH+ terminals and
neurons in the striatum and SNc, respectively (Shughrue, 2004;
Almey et al., 2012).
In the present study, we found that OVX mice—which had
undergone ovariectomy at the seventh week of life—showed
greater loss of dopaminergic cell bodies in the SNc, as compared
to the other experimental groups, at later time points (7 and 14
days post-6-OHDA). Remarkably, estrogen treatment reversed
this change, OVX+Emice showing reduced loss of dopaminergic
neurons in the SNc, 24 h, 7 and 14 days after 6-OHDA infusion,
compared with OVX group, suggesting that estrogens treatment
provide neuronal protection when it is given immediately after an
ovariectomy. In addition, hormone deprivation worsens, while
the constant exposure to estrogens relieves the damage induced
by the neurotoxin in female mice. Probably, in OVX mice with
estrogen deprived, the limited exposure to estrogenic stimulation
during the fertile life caused an increased susceptibility of the
nigrostriatal pathway to the neurotoxin. Accordingly, previous
studies have shown that exposure to estrogens during the fertile
life contributes to decrease the risk of PD (Ragonese et al., 2006a).
Immunoreactive microglia have been reported in both human
brains and experimental models of PD, not only in the SNc, but
also in the striatum, hippocampus and cortical areas implicated
in disease (McGeer et al., 1988; Banati et al., 1998; Mirza et al.,
2000). In addition, studies using the 6-OHDA model in rodents
showed increased microgliosis associated with degeneration of
dopaminergic neurons (Marinova-Mutafchieva et al., 2009).
However, it is not yet clear whether the reactive microglia is a
cause or effect of neuronal damage during disease progression,
although studies support the idea that activation of microglia and
thus inflammatory changes contribute to the disease processes.
In this study we showed that microglia is activated at earlier
time points (1 and 2 days after 6-OHDA infusion) in the SNc of all
experimental groups (Armentero et al., 2006; Virgone-Carlotta
et al., 2013; Haas et al., 2016), but in male and female mice,
then starts receding at day 7 and disappears at the latest time
point (day 14). Here we also observed that IBA1+ cell density
and activation is increased in OVX mice at different time points
(24 h and 2 days after surgery) as compared to OVX+E mice
and microglia activation, in OVX mice, remained elevated at all
time points. We demonstrate that estrogen treatment restored
the profile of microglia activation observed in male and female
mice, confirming the dampening effects of estrogens onmicroglia
activation.
Microglia can be polarized toward different phenotypes:
cytotoxic M1 and neuroprotective M2 (Hu et al., 2012; Blandini,
2013; Joers et al., 2016). Transient activation of microglia is
generally neuroprotective, but a chronic reactivity of these cells
concur to the release of different cytotoxic molecules, such
as reactive oxygen species, chemokines and pro-inflammatory
cytokines (Su and Federoff, 2014), which play a pivotal role in PD
neurodegeneration (Lull and Block, 2010; Perego et al., 2011). In
this study we observed that the changes in microglial activation
in the experimental groups were associated with significant
differences in the polarization patterns, in particular among OVX
mice and OVX mice treated with estrogen.
Our results demonstrate that in all experimental groups at
1 day after surgery microglial cells are polarized toward a
CD206+(M2) phenotype, suggesting that the prevalent response
of microglia in the early phases of neurotoxicity corresponds
to a neuroprotective function. Nevertheless, 2 days after 6-
OHDA injection microglia remained polarized toward the M2
phenotype only in female mice and OVX treated with estrogens.
By contrast, in OVX mice we observed a prevalence of TNF-
α+ microglia, compared to the other experimental groups, 14
days after surgery. Microglia activation polarized toward M1
phenotype was associated with a strong neuronal damage in OVX
mice. By contrast OVX+E mice mainly showed a M2 phenotype
and a significant reduction of damage in SNc. Additionally, the
number of IBA1+ cells is significantly increase in OVX mice
injected with placebo as compared to OVX mice treated with
estrogen at 1 and 2 days after 6-OHDA infusion. These results
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strongly support that estrogen triggers pro-resolution effects on
microglia, corroborating existing evidence obtained in cellular
systems (Villa et al., 2015). Furthermore, these data allow to
further strengthen the hypothesis that M2 polarized microglia
participates in neuroprotection (Hu et al., 2012).
As for the astrocytic response to 6-OHDA, astroglia activation
manifested at later time-points in all experimental groups.
In OVX mice, astroglial activation showed the same pattern
observed in intact mice, but was more intense, as compared
to the other experimental groups, and decreased in OVX+E
mice. In keeping with our observation, other studies have
reportedmild astroglial activation in the first week post-6-OHDA
infusion, followed by more intense activation in the second
week (Ambrosi et al., 2017). Astrocytes may either counteract
or favor the neurodegenereative process, depending on the
molecules released into the extracellular space and, consequently,
the microenvironment shared with neurons (Johann and Beyer,
2013). Astrocytes can be directly activated by cytokines, such as
TNF-α and IL-1β, released from microglia, thus leading to the
production of free radicals and increasing the neuronal damage
(Johann and Beyer, 2013). Changes in the microglia pattern
of activation and polarization associated with ovariectomy,
and restored after estrogenic treatment, may have therefore
modulated astroglial reactivity. Furthermore, experiments in
animal models have shown that the reduction of the astrocytes
activation may also be linked to the reduction of neuronal
damage, relative to a lower release of factors able to promote
the astrogliosis (Ahaz-Fonseca et al., 2014). This effect could
be mediated, once again, by interaction with ERs which could
suffer a strengthening following infusion of 6-OHDA (Dang et al.,
2011).
Limitation of the Study and Future
Directions
It is known that ER activation in inflammatory cells plays a major
role in the cytoprotective effect of estrogens and in the regulation
of cerebral cytokines expression (Soucy et al., 2005). Additionally,
in these cells, estrogens regulate protein expression involved both
in inflammation and in remodeling of the extracellular matrix
(Stygar et al., 2007). The present findings support that estrogen
neuroprotection may be mediated by a direct effect on microglia,
probably through the activation of the ER present on these cells
(Vegeto et al., 2001, 2003). However, a limitation of the study
resides in the lack of exploration of the selective ERs role and
molecular mechanisms of estrogen-microglia signals underlying
M2 polarization in the model used in this study. Consequently,
future studies will be needed to define the influence of ERs
on microglia activation related to 6-OHDA administration that
induces neurodegeneration in ERs-KO mice.
CONCLUSIONS
The identification of new therapeutic approaches able to stop
or slow down the neuronal degeneration represents one of
the major goals of current research in the PD field. Here, we
have been demonstrated that estrogenic treatment is able to
modify astroglia and microglia activation, microglia cell density,
modulating the progression of nigrostriatal degeneration of PD.
Future studies will be conduct for the development of “estrogen-
like compounds” able tomaximize the neuroprotective effect and,
at the same time, to reduce the undesirable effects.
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